Drug intelligence / Profile preview

acetylcysteine + paracetamol + phenylephrine

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

A combination pharmaceutical product containing **acetylcysteine**, **paracetamol** (also known as acetaminophen), and **phenylephrine**. - **Acetylcysteine** acts as a mucolytic agent by breaking down disulfide bonds in mucus, reducing its viscosity and facilitating expectoration. It also functions as an antioxidant and is used as an antidote for paracetamol overdose by replenishing glutathione stores. - **Paracetamol** is an analgesic and antipyretic, primarily lowering fever and relieving mild to moderate pain by inhibiting prostaglandin synthesis in the central nervous system and acting on the hypothalamic heat-regulating center. - **Phenylephrine** is a sympathomimetic decongestant that selectively activates alpha-1 adrenergic receptors, leading to vasoconstriction of nasal blood vessels and relief of nasal congestion. This combination is produced for symptomatic treatment of the **common cold** and associated upper respiratory symptoms such as fever, headache, body aches, mucus overproduction, cough, and nasal congestion[1].

02

Targets

COXADRA1A (α1A)

Beyond the preview

Go deeper on acetylcysteine + paracetamol + phenylephrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetylcysteine + paracetamol + phenylephrine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call